medigraphic.com
Instituto Nacional de Salud Pública

2018, Número 6

<< Anterior Siguiente >>

salud publica mex 2018; 60 (6)


Incidence, psychosocial burden, and economic impact of genital warts in Mexico

Domenech-Viñolas M, León-Maldonado L, Ramírez-Palacios P, Flores YN, Granados-García V, Brown B, Corona E, Liu S, Lazcano-Ponce E, Salmerón J

Idioma: Ingles.
Referencias bibliográficas: 31
Paginas: 624-632
Archivo PDF: 399.77 Kb.


RESUMEN

Objetivo. Estimar la carga por verrugas genitales (VG) en México. Material y métodos. Estimamos la incidencia anual de VG, con base en información proporcionada por médicos especialistas y el manejo de las VG, así como el costo promedio del tratamiento y la carga psicosocial de las VG. Resultados. La incidencia anual de VG en México fue de 547 200 casos. Los tratamientos variaron según la especialidad y el sexo del paciente. El costo anual por VG fue de $195 millones de dólares estadounidenses. El impacto psicosocial de las VG es ligeramente mayor en hombres que en mujeres. Conclusiones. Esta es la primera evaluación de la carga de VG en México. Los datos sugieren que las VG son frecuentes, tienen costos relacionados con salud e impactos psicosociales significativos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol. 1999;37(10):3316-22.

  2. Hernandez-Suarez G, Pineros M, Vargas JC, Orjuela L, Hernandez F, Peroza C, et al. Human papillomavirus genotypes in genital warts in Latin America: a cross-sectional study in Bogota, Colombia. Int J STD AIDS. 2013;24(7):567-72. https://doi.org/10.1177/0956462412474538

  3. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12-23. https://doi.org/10.1016/j.vaccine. 2012.07.055

  4. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24(Suppl 3):S3/35-41.

  5. Parkin DM, Louie KS, Clifford G. Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region. Vaccine. 2008;26(Suppl 12):M1-16. https://doi.org/10.1016/j.vaccine. 2008.05.010

  6. Préaud E, Largeron N. Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review. J Med Econ. 2013;16(6):763-76. https://doi.org/10.3111/13696998.2013.793691

  7. Dominiak-Felden G, Cohet C, Atrux-Tallau S, Gilet H, Tristram A, Fiander A. Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, healthrelated quality of life study in the UK. BMC Public Health. 2013;13:1065. https://doi.org/10.1186/1471-2458-13-1065

  8. Coles VA, Chapman R, Lanitis T, Carroll SM. The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland. Int J STD AIDS. 2016;27(1):51-7. https://doi. org/10.1177/0956462415573121

  9. Brotherton JM, Heywood A, Heley S. The incidence of genital warts in Australian women prior to the national vaccination program. Sex Health. 2009;6(3):178-84. https://doi.org/10.1071/SH08079

  10. Park IU, Introcaso C, Dunne EF. Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis. 2015;61 Suppl 8:S849-55. https://doi. org/10.1093/cid/civ813

  11. Scarbrough-Lefebvre CD, Van Kriekinge G, Gonçalves MA, de Sanjose S. Appraisal of the burden of genital warts from a healthcare and individual patient perspective. Public Health. 2011;125(7):464-75. https://doi. org/10.1016/j.puhe.2011.01.016

  12. Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Piñeros M. Burden and trends of type-specific human papillomavirus infections and related diseases in Latin America and Caribbean region. Vaccine. 2008;26 (Suppl 11):L1-15. https://doi.org/10.1016/j.vaccine.2008.05.043

  13. Tejada RA, Vargas KG, Benites-Zapata V, Mezones-Holguín E, Bolaños- Díaz R, Hernandez AV. Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis. Salud Publica Mex. 2017;59(1):84-94. https://doi.org/10.21149/7824

  14. Simms I, Fairley CK. Epidemiology of genital warts in England and Wales: 1971 to 1994. Genitourin Med. 1997;73(5):365-7.

  15. Franceschi S, Doll R, Gallwey J, La Vecchia C, Peto R, Spriggs AI. Genital warts and cervical neoplasia: an epidemiological study. Br J Cancer. 1983;48(5):621-8.

  16. Canvin M, Sinka K, Hughes G, Mesher D. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect. 2017;93(2):125-8. https://doi.org/10.1136/sextrans- 2016-052626

  17. Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13:39. https:// doi.org/10.1186/1471-2334-13-39

  18. Perez G, Lazcano-Ponce E, Hernandez-Avila M, García PJ, Muñoz N, Villa LL, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008;122(6):1311-8.

  19. Anic GM, Lee JH, Stockwell H, Rollison DE, Wu Y, Papenfuss MR, et al. Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study. J Infect Dis. 2011;204(12):1886-92. https://doi.org/10.1093/infdis/jir652

  20. Lacey CJN. Genital warts and mucosal papillomavirus disease. Med (United Kingdom). 2014;42(7):349-53. https://doi.org/10.1016/j. mpmed.2014.04.012

  21. Pirotta M, Stein AN, Conway EL, Harrison C, Britt H, Garland S. Genital warts incidence and healthcare resource utilisation in Australia. Sex Transm Infect. 2010;86(3):181-6. https://doi.org/10.1136/sti.2009.040188

  22. Raymakers AJ, Sadatsafavi M, Marra F, Marra CA. Economic and humanistic burden of external genital warts. Pharmacoeconomics. 2012;30(1):1- 16. https://doi.org/10.2165/11591170-000000000-00000

  23. Castellsagué X, Cohet C, Puig-Tintoré LM, Acebes LO, Salinas J, San Martin M, et al. Epidemiology and cost of treatment of genital warts in Spain. Eur J Public Health. 2009;19(1):106-10. https://doi.org/10.1093/ eurpub/ckn127

  24. Scarbrough-Lefebvre CD, Van Kriekinge G, Gonçalves MA, de Sanjose S. Appraisal of the burden of genital warts from a healthcare and individual patient perspective. Public Health. 2011;125(7):464-75. https://doi. org/10.1016/j.puhe.2011.01.016

  25. Mast TC, Zhu X, Demuro-Mercon C, Cummings HW, Sings HL, Ferris DG. Development and psychometric properties of the HPV Impact Profile (HIP) to assess the psychosocial burden of HPV. Curr Med Res Opin. 2009;25(11):2609-19. https://doi.org/10.1185/03007990903238786

  26. Vilata JJ, Varela JA, Olmos L, Colombo JA, Llorens MA, de los Terreros MS, et al. ECCAVIM Study Group. Validation and clinical use of the CECA, a disease-specific quality of life questionnaire for patients with anogenital condylomata acuminata. Acta Derm Venereol. 2008;88(3):257-62. https:// doi.org/10.2340/00015555-0422

  27. Greenlaw C, Brown-Welty S. A comparison of web-based and paper-based survey methods: testing assumptions of survey mode and response cost. Eval Rev. 2009;33(5):464-80. https://doi. org/10.1177/0193841X09340214

  28. Vittori G, Matteelli A, Boselli F, Naldi L, Gialloreti LE. A new approach to estimate Genital Warts incidence and prevalence in the Italian general female population. Ital J Gynaecol Obstet. 2008;20(1):33-42.

  29. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando- Hernández S, Franco A, Cuevas-Nasu L. et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, México: Instituto Nacional de Salud Pública, 2012.

  30. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805-14. https://doi.org/10.1086/597071

  31. Brown B, Davtyan M, Leon SR, Sanchez H, Calvo G, Klausner JD, Galea J. A prospective cohort study characterising the role of anogenital warts in HIV acquisition among men who have sex with men: a study protocol. BMJ Open. 2014;4(9):e005687.




2020     |     www.medigraphic.com